STAT+: FDA approves AstraZeneca breast cancer drug

The headline announces an FDA approval for an AstraZeneca breast cancer drug, but the excerpt does not specify which drug or provide additional regulatory details.

The accompanying newsletter text teases other stories in the issue: Roivant has delivered standout mid-stage results for its pulmonary hypertension drug, Moonwalk has raised funds to develop longer-lasting obesity drugs, and an FDA approval has paradoxically complicated access to Revolution Medicines' new pancreatic cancer drug for some patients. The article is part of STAT+'s The Readout newsletter by Meghana Keshavan.